Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A
Open Access
- 27 June 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 930435
- https://doi.org/10.3389/fneur.2022.930435
Abstract
With therapeutic trials on the horizon for Charcot-Marie-Tooth type 1A (CMT1A), reliable, valid, and responsive clinical outcome assessments and biomarkers are essential. Accelerate Clinical Trials in CMT (ACT-CMT) is an international study designed to address important gaps in CMT1A clinical trial readiness including the lack of a validated, responsive functional outcome measure for adults, and a lack of validated biomarkers for multicenter application in clinical trials in CMT1A. The primary aims of ACT-CMT include validation of the Charcot-Marie-Tooth Functional Outcome Measure, magnetic resonance imaging of intramuscular fat accumulation as a lower limb motor biomarker, and in-vivo reflectance confocal microscopy of Meissner corpuscle sensory receptor density, a sensory biomarker. Initial studies have indicated that these measures are feasible, reliable and valid. A large prospective, multi-site study is necessary to fully validate and examine the responsiveness of these outcome measures in relation to existing outcomes for use in future clinical trials involving individuals with CMT1A. Two hundred 15 adults with CMT1A are being recruited to participate in this prospective, international, multi-center study. Serial assessments, up to 3 years, are performed and include the CMT-FOM, CMT Exam Score-Rasch, Overall Neuropathy Limitations Scale, CMT-Health Index, as well as nerve conduction studies, and magnetic resonance imaging and Meissner corpuscle biomarkers. Correlations using baseline data will be examined for validity. Longitudinal analyses will document the changes in function, intramuscular fat accumulation, Meissner corpuscle sensory receptor density. Lastly, we will use anchor-based and other statistical methods to determine the minimally clinically important change for these clinical outcome assessments and biomarkers in CMT1A. Reliable, and responsive clinical outcome assessments of function and disease progression biomarkers are urgently needed for application in early and late phase clinical trials in CMT1A. The ACT-CMT study protocol will address this need through the prospective, longitudinal, multicenter examination in unprecedented detail of novel and existing clinical outcome assessments and motor and sensory biomarkers, and enhance international clinical trial infrastructure, training and preparedness for future therapeutic trials in CMT and related neuropathies.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke
This publication has 42 references indexed in Scilit:
- Patient Identification of the Symptomatic Impact of Charcot–Marie–Tooth Disease Type 1AJournal of Clinical Neuromuscular Disease, 2013
- Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disabilityAnnals of Neurology, 2012
- Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trialThe Lancet Neurology, 2011
- P2X7-mediated Increased Intracellular Calcium Causes Functional Derangement in Schwann Cells from Rats with CMT1A NeuropathyOnline Journal of Public Health Informatics, 2009
- Charcot-Marie-Tooth and pain: correlations with neurophysiological, clinical, and disability findingsNeurological Sciences, 2008
- Relationship between clinical examination, Quality of Life, disability and depression in CMT patients: Italian Multicenter studyNeurological Sciences, 2008
- A modified peripheral neuropathy scale: the Overall Neuropathy Limitations ScaleJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Analyzing incomplete longitudinal clinical trial dataBiostatistics, 2004
- Measurement of health status: Ascertaining the minimal clinically important differenceControlled Clinical Trials, 1989
- Can the Sickness Impact Profile measure change? An example of scale assessmentJournal of Chronic Diseases, 1986